Does Accelerated Approval Deliver Accelerated Access?

EXPERIENCES, CHALLENGES AND PRIORITIES

at ISPOR 20th Annual European Congress

13:00-14:00 | 8th November

Lomond Auditorium, Loch Suite, Scottish Event Campus

An educational symposium featuring short presentations from a panel of experts, followed by an interactive Q&A session with the audience.

Panos Kanavos
Associate Professor in International Health Policy,
London School of Economics and Political Science

Victoria Tzouma
Associate Director in Health Economics and Policy,
London School of Economics and Political Science

Kate Morgan
Policy and Public Affairs Manager,
Myeloma Patients Europe

Chris Hoyle
Director Health Economics & Payer Analytics,
AstraZeneca

Sponsored by

AstraZeneca

Hosted by

LSE THE LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE

Accelerated regulatory pathways have the potential to dramatically change the treatment paradigm for a number of conditions. However, rapid regulatory approval does not guarantee rapid patient access.

This symposium will explore ongoing London School of Economics (LSE) research into the impact of HTA and value assessment on cancer drugs approved through accelerated pathways.

Differences in approach and evidence requirements will be discussed and representatives from industry, academia and patient groups will share experiences and perspectives.

The audience will be invited to contribute their thoughts on the existing challenges and determine priorities for ensuring sustainable solutions that provide appropriate patient access to innovative treatments.

Time	Content	Speaker
13.00	Chair's welcome and introductions	Victoria Tzouma
13.05	**Are Accelerated Approval Mechanisms a Predictor to Early Access and Coverage?**	Panos Kanavos
13.15	**Analytical Approaches and Practical Challenges – Industry perspectives from a recent example**	Chris Hoyle
13.25	**Meeting Patient Expectations of Accelerated Approval**	Kate Morgan
13.35	Discussion and interactive Q&A	Moderated by Victoria Tzouma

This symposium was convened with financial support from AstraZeneca. Panellists Panos Kanavos, Victoria Tzouma and Kate Morgan retained editorial control over all presentation materials and content and the views or opinions expressed by them are not necessarily those of AstraZeneca.

This symposium is part of a London School of Economics research project supported by AstraZeneca. The findings will be published in summer 2018.